lapatinib has been researched along with prasugrel in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (prasugrel) | Trials (prasugrel) | Recent Studies (post-2010) (prasugrel) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 18 | 0 | 16 |
| Protein | Taxonomy | lapatinib (IC50) | prasugrel (IC50) |
|---|---|---|---|
| P2Y purinoceptor 12 | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
1 review(s) available for lapatinib and prasugrel
| Article | Year |
|---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |